What are the benefits of initiating empagliflozin (10 mg) once daily in a patient with chronic heart failure (reduced or preserved ejection fraction) who does not have type 1 diabetes, active ketoacidosis, or an eGFR < 30 mL/min/1.73 m²?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Benefits of Empagliflozin 10 mg Daily in Chronic Heart Failure

Empagliflozin 10 mg once daily significantly reduces cardiovascular death and heart failure hospitalizations in patients with chronic heart failure (both reduced and preserved ejection fraction), regardless of diabetes status, and should be initiated in eligible patients to improve mortality, morbidity, and quality of life.

Primary Cardiovascular Benefits

Mortality and Hospitalization Reduction

Empagliflozin provides robust benefits across the ejection fraction spectrum:

  • Heart Failure with Reduced Ejection Fraction (HFrEF, EF ≤40%): In EMPEROR-Reduced, empagliflozin reduced the composite of cardiovascular death or heart failure hospitalization by 21% (HR 0.79,95% CI 0.69-0.90) over a median of 26.2 months 1. The benefit was evident within 12 days of initiation and sustained throughout follow-up 2.

  • Heart Failure with Preserved Ejection Fraction (HFpEF, EF >40%): In EMPEROR-Preserved, empagliflozin reduced the same composite endpoint by 21% (HR 0.79,95% CI 0.69-0.90) over 26.2 months 3, 4. This effect was primarily driven by a 29% reduction in heart failure hospitalizations 5.

  • Across the EF Spectrum: The benefit is consistent across ejection fractions from <25% to <65%, with approximately 30% reduction in heart failure hospitalizations across all subgroups 6. The effect appears attenuated only in patients with EF ≥65% 6.

Cardiovascular Death Specifically

Empagliflozin reduces cardiovascular death by 38% (HR 0.62,95% CI 0.49-0.77) in patients with type 2 diabetes and established cardiovascular disease 7. This mortality benefit is consistent regardless of baseline diabetes status 3, 8.

Hospitalization Benefits

Reduction in Heart Failure Events

  • First Hospitalizations: 35% reduction in initial heart failure hospitalization in EMPA-REG OUTCOME 3
  • Total Hospitalizations: 30% reduction in total (first and recurrent) heart failure hospitalizations (HR 0.70,95% CI 0.58-0.85) 3
  • Intensive Care Admissions: 33% reduction in heart failure hospitalizations requiring intensive care (HR 0.67,95% CI 0.50-0.90) 2
  • High-Acuity Events: 36% reduction in hospitalizations requiring vasopressors, inotropes, or mechanical intervention (HR 0.64,95% CI 0.47-0.87) 2

Outpatient Worsening Events

Empagliflozin reduces emergent/urgent heart failure visits requiring intravenous treatment by 24% (HR 0.76,95% CI 0.67-0.87), with benefits apparent within 12 days 2. The drug also reduces diuretic intensification needs by 33% (HR 0.67,95% CI 0.56-0.78) 2.

Renal Protection

Kidney Function Preservation

Empagliflozin slows estimated glomerular filtration rate (eGFR) decline regardless of baseline kidney function:

  • 50% reduction in composite renal outcomes (chronic dialysis, transplantation, or sustained eGFR reduction) in patients with diabetes and cardiovascular disease (HR 0.50,95% CI 0.32-0.77) 3
  • Consistent renal benefits across all KDIGO risk categories (low, moderate, high, and very high risk) 9
  • The renal protective effect is present in patients with eGFR as low as 20 mL/min/1.73 m² 1, 10

Important caveat: The drug is contraindicated in patients with eGFR <30 mL/min/1.73 m² for glycemic control, but can be used for heart failure indications down to eGFR ≥20 mL/min/1.73 m² 11, 7.

Quality of Life Improvements

Functional Status

  • NYHA Class Improvement: Patients are 20-40% more likely to experience improvement in NYHA functional class, with effects apparent at 28 days and maintained long-term 2
  • NYHA Class Stabilization: 20-40% reduction in risk of NYHA class worsening 2

Symptom Relief

Empagliflozin improves Kansas City Cardiomyopathy Questionnaire (KCCQ) scores across all ejection fraction categories 1, 6. The improvement in quality of life is consistent regardless of frailty status, though the magnitude may be slightly reduced in severely frail patients 12.

Benefits Independent of Diabetes Status

A critical distinction: Empagliflozin's heart failure benefits are independent of diabetes status and glucose-lowering effects 3, 1, 8. In EMPEROR-Preserved, approximately 50% of patients had diabetes at baseline, and treatment effects were consistent in those with and without diabetes (P-interaction = 0.92) 8. The drug works through mechanisms beyond glycemic control, including hemodynamic effects, reduced oxidative stress, and improved endothelial function 13.

Timing of Benefit

Benefits emerge rapidly: Statistical significance for the composite endpoint is reached within 12 days of initiation 2. This early benefit supports prompt initiation rather than delayed treatment.

Safety Considerations in This Population

Appropriate Use

  • Initiate at 10 mg once daily (the dose studied in heart failure trials) 3, 1, 13
  • Can be used in patients with eGFR ≥20 mL/min/1.73 m² for heart failure indications 1, 5
  • Safe across frailty spectrum, though monitor closely in severely frail patients 12
  • Consistent benefits in ischemic and non-ischemic heart failure 14
  • Safe in patients with atrial fibrillation (may reduce incident AF, HR 0.66,95% CI 0.40-1.09) 15

Contraindications Per Your Patient Criteria

Your patient appropriately excludes:

  • Type 1 diabetes (contraindicated for SGLT2 inhibitors)
  • Active ketoacidosis (contraindicated)
  • eGFR <30 mL/min/1.73 m² (though can use down to 20 for HF indication per recent data)

Common Adverse Events to Monitor

  • Genital and urinary tract infections (more common than placebo) 4
  • Volume depletion/hypotension (monitor, especially if on aggressive diuretics) 7
  • Rare: diabetic ketoacidosis (even in non-diabetics under extreme stress)

Meta-Analysis Evidence

A large meta-analysis of 21,947 patients across five major SGLT2 inhibitor trials (EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, SOLOIST-WHF) demonstrated consistent reductions in:

  • Composite of cardiovascular death or heart failure hospitalization
  • Cardiovascular death alone
  • First hospitalization for heart failure
  • All-cause mortality 3, 1

These findings establish SGLT2 inhibitors as a class effect for heart failure across the ejection fraction spectrum.

Guideline Recommendations

The 2024 ADA Standards of Care state that in people with type 2 diabetes and established HFpEF or HFrEF, an SGLT2 inhibitor with proven benefit is recommended to reduce worsening heart failure and cardiovascular death 1. The 2022 AHA/ACC/HFSA guidelines give empagliflozin a Class 2a recommendation (Level of Evidence B-R) for HFmrEF and established benefits in HFrEF 5.

The 2025 Canadian guidelines recommend SGLT2 inhibitors as cornerstone therapy for heart failure across the ejection fraction spectrum, with empagliflozin 10 mg daily as the starting dose 13.

References

Research

Empagliflozin in Heart Failure with a Preserved Ejection Fraction.

The New England journal of medicine, 2021

Related Questions

Is the patient a candidate for Jardiance (empagliflozin) given heart failure with preserved ejection fraction, severe coronary artery disease, combined pulmonary fibrosis‑emphysema, and current use of Breztri (beclomethasone/formoterol/glycopyrrolate)?
How does Jardiance (empagliflozin) benefit patients with heart failure with preserved ejection fraction?
What is the recommended empagliflozin (Jardiance) dose for patients with heart failure with preserved ejection fraction?
Is Jardiance (empagliflozin) beneficial for patients with Hypertrophic Cardiomyopathy (HCM) and normal ejection fraction (EF) who have atrial flutter and are on Eliquis (apixaban)?
Are empagliflozin (Jardiance) and eplerenone appropriate for a patient with preserved left ventricular ejection fraction, mild left‑ventricular chamber enlargement and grade 1 diastolic dysfunction, despite lacking systolic dysfunction?
What causes Modic type I and type II changes in the cervical spine?
Is oral antibiotic therapy indicated after removal of an infected nail plate in a healthy adult without signs of ongoing infection?
What empiric intravenous antimicrobial regimen should be used for an adult patient with confirmed gram‑negative rod bacteremia and no known drug allergies?
How should delirium in an elderly patient be managed?
What antibiotic regimen provides coverage for methicillin‑resistant Staphylococcus aureus (MRSA), anaerobic bacteria, and gram‑negative organisms?
Why am I now having liquid stool leakage after my fistulotomy, given I had a lateral internal sphincterotomy (LIS) performed during hemorrhoidectomy four years ago?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.